Email: nbansback@cheos.ubc.ca

Phone: (1) 604-682-2344 (63561)

Health Economist, Centre for Health Evaluation and Outcome Sciences, Vancouver, Canada

PhD student, Health Economics and Decision Sciences, University of Sheffield, UK

ongoing    PhD Health Economics (University of Sheffield) expected completion 2010

2004        MSc Health Services Research (University of Sheffield)

2000        BSc Mathematics (University of Sheffield)

• Bansback et al., "Patient reported outcomes for rheumatoid arthritis: where are we and where are we going?"
• Bansback and Marra, "Now that we know what's BeSt, what is good value for the money?"
• Brennan and Bansback, "Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?"
• Bansback et al., "The NICE reappraisal of biologics in 2005: what rheumatologists need to know"

• Ward et al., "Gemcitabine: a Systematic Review"

• "Nixons recent poster"
• Marra, C et al., "Mapping Health Utility Values From The HAQ Index: Should This Approach Be Used."
• Harrison, M et al., "Health Status in Inflammatory Arthritis Patients with "Worse Than Death" EQ-5D Scores."
• Zhang, W et al., "Short-Term Impact of Adalimumab on Productivity Outcomes in Patients with Rheumatoid Arthritis."
• Finckh, A et al., "Costs and Benefits of Strategies for Treating New Onset Rheumatoid Arthritis within 12 Weeks."
• Harrison, M et al., "Why do patients with rheumatoid arthritis often score 'states worse than death' on the EQ-5D?"
• Bansback, N et al., "Health State Utility Values In Rheumatic Diseases – A Review."
• Marra, C et al., "Predicting Preference-Based Measures from the HAQ-DI and the RAQOL."
• Finckh, A et al., "The Evolution of Functional Capacity in Relation to Disease Activity over the Course of Rheumatoid Arthritis."
• Harrison, M et al., "The Comparative Measurement Properties of the EQ5D and SF6D Health Utility Measures in Patients with Rheumatoid Arthritis."
• Bansback, N et al., "Using Value of Information in the Development of Clinical Trials: A Case Study of Statin Therapy in Patients with Rheumatoid Arthritis."
• Sun, H et al., "Designing Economic Evaluations in Late-Stage HIV: What Health States should be Included?"
• Nosyk, B et al., "Economic Methods in Budgetary Impact Analysis: A Critical Review."
• Anis, A et al., "Does the length of recall time matter in measuring health status and quality of life in patients with HIV/AIDS?"
• Bansback, N et al., "A review of economic evaluations in ankylosing spondylitis: considerations and proposal for an OMERACT reference case."
• Brennan, A et al., "The cost effectiveness of anti-TNF antagonists in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry."
• Bansback, N et al., "Measuring health status and quality of life in patients with HIV/AIDS: Does the length of recall time make a difference?"
• Anis, A et al., "Determinants of Health State Utility in patients with Psoriatic Arthritis."
• Anis, A et al., "Improvement in Health Utility in patients with Psoriatic Arthritis treated with Adalimumab."
• Bansback, N et al., "The impact of recall time on the measurement of Health Utilities for Acute Events."
• Bansback, N et al., "Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira®)"
• Bansback, N et al., "Determinants of health state utility in patients with Psoriatic Arthritis."
• Brazier, J et al., "Are generic preference-based measures truly generic? The case of visually impaired patients."
• Carlton, J et al., "A Survey of Quality of Life in Patients with Age Related Macular Degeneration."
• Czoski, Murray, C et al., "Comparison of preference-based measures in patients with Age Related Macular Degeneration."
• Espallargues, M et al., "Health status measurement in age-related macular disease: new evidence for clinical and economic evaluation."
• Bansback, N et al., "Cost-effectiveness of adalimumab (Humira) in the treatment of US patients with Rheumatoid Arthritis (RA)."
• Bansback, N et al., "The Economic implications of TNF-α inhibitors in the treatment of Psoriatic Arthritis"
• Bansback, N et al., "Cost-effectiveness analyses of TNF antagonists in rheumatoid arthritis: A review."
• Brazier, J et al., "The relationship between impairment, societal preferences, patient state values and patient satisfaction in age-related Macular Degeneration."
• Bansback, N et al., "The cost Effectiveness of adalimumab (Humira®) in patients with RA: A Finnish analysis."
• Bansback, N et al., "The cost effectiveness of adalimumab (Humira®) in UK patients with moderate to severe RA."
• Bansback, N et al., "The cost-effectiveness of adalimumab (Humira) in patients with Rheumatoid Arthritis: A UK analysis."
• Bansback, N et al., "Which patients with early RA develop fast progressive disease? Prognostic factors for severe functional loss from an inception cohort with 9 year follow up."
• Bansback, N et al., "Cost Effectiveness of Adalimumab (HUMIRA™, Abbott) in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis (RA)"
• Bansback, N et al., "Identifing Groups of RA Patients Who are Fast Progressors from Early Clinical and Radiological Data"
• Bansback, N et al., "The Cost-effectiveness of Adalimumab (HUMIRA™, Abbott) in Patients with Rheumatoid Arthritis: a Swedish Analysis"
• Brennan, A et al., "Methods to analyse the economic benefits of a pharmacogenetic (PGt) test to predict response to biologic therapy in RA, and to prioritise further research"
• Brennan, A et al., "Methods to analyse the economic benefits of a pharmacogenetic (PGt) test to predict response to biologic therapy in RA, and to prioritise further research"
• Bansback, N et al., "Impact Of Direct And Indirect Costs On The Cost-Effectiveness Of Etanercept In Rheumatoid Arthritis In The UK"
• Bansback, N et al., "The cost-effectiveness of 3rd Line etanercept versus other DMARDs in adults with Rheumatoid Arthritis in the UK"
• Bansback, N et al., "The need for a Monte Carlo patient history modelling approach when comparing the cost-effectiveness of etanercept against different DMARD sequences"
• Bansback, N et al., "Modelling the cost-effectiveness of etanercept in adults with Rheumatoid Arthritis (RA) in the UK"
• Bansback, N et al., "In Rheumatoid Arthritis (RA) utility calculations should be derived from the EQ5D rather than the SF-36 due to floor effects"
• Brennan, A et al., "Modelling the cost-effectiveness of etanercept in adults with Rheumatoid Arthritis (RA) in the UK"
• Bansback, N et al., "How useful are disease specific reference cases for improving economic evaluations? A systematic review"
• Bansback, N et al., "An application of Value of Information analysis to help design a multi centre clinical trial"
• Bansback, N et al., "Using Economic Methods to Efficiently Design Clinical Trials: A Case Study of Statin Therapy in Patients with Rheumatoid Arthritis"
• Bansback, N et al., "Statin therapy for patients with rheumatoid arthritis: a cost effectiveness analysis"
• Bansback, N et al., "A prognostic model for progressive disease in Early Rheumatoid Arthritis"
• Bansback et al., "A threshold cost effectiveness comparison of infliximab and etanercept in adults with rheumatoid arthritis in the UK"